ATE188487T1 - Anti-gp39 antikoerper und deren verwendungen - Google Patents

Anti-gp39 antikoerper und deren verwendungen

Info

Publication number
ATE188487T1
ATE188487T1 AT94926659T AT94926659T ATE188487T1 AT E188487 T1 ATE188487 T1 AT E188487T1 AT 94926659 T AT94926659 T AT 94926659T AT 94926659 T AT94926659 T AT 94926659T AT E188487 T1 ATE188487 T1 AT E188487T1
Authority
AT
Austria
Prior art keywords
cell
receptor
antigen
methods
ligand
Prior art date
Application number
AT94926659T
Other languages
English (en)
Inventor
Randolph J Noelle
Teresa M Foy
Alejandro Aruffo
Jeffrey A Ledbetter
Original Assignee
Dartmouth College
Bristol Myers Squibb Pharmaceu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE188487(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College, Bristol Myers Squibb Pharmaceu filed Critical Dartmouth College
Application granted granted Critical
Publication of ATE188487T1 publication Critical patent/ATE188487T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94926659T 1993-09-02 1994-09-02 Anti-gp39 antikoerper und deren verwendungen ATE188487T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11625593A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009871 WO1995006666A1 (en) 1993-09-02 1994-09-02 Anti-gp39 antibodies and uses therefor

Publications (1)

Publication Number Publication Date
ATE188487T1 true ATE188487T1 (de) 2000-01-15

Family

ID=26814047

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94926659T ATE188487T1 (de) 1993-09-02 1994-09-02 Anti-gp39 antikoerper und deren verwendungen
AT94926677T ATE167062T1 (de) 1993-09-02 1994-09-02 Verfahren zur anregung antigenspezifischer t- zelltoleranz

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94926677T ATE167062T1 (de) 1993-09-02 1994-09-02 Verfahren zur anregung antigenspezifischer t- zelltoleranz

Country Status (17)

Country Link
US (5) US5747037A (de)
EP (2) EP0721346B1 (de)
JP (3) JP2991499B2 (de)
CN (2) CN100341896C (de)
AT (2) ATE188487T1 (de)
AU (2) AU696235B2 (de)
DE (2) DE69411025T2 (de)
DK (2) DK0721346T3 (de)
ES (2) ES2120067T3 (de)
FI (2) FI106306B (de)
GR (2) GR3027658T3 (de)
HU (2) HU220296B (de)
IL (1) IL110855A (de)
NO (2) NO321036B1 (de)
NZ (3) NZ273221A (de)
PT (1) PT721469E (de)
WO (2) WO1995006481A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
ATE188487T1 (de) * 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JPH08239324A (ja) * 1995-03-03 1996-09-17 Fusanori Hamashima 免疫抑制剤
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
DE19634159C1 (de) * 1996-08-23 1997-09-25 Gsf Forschungszentrum Umwelt Induktion einer Tumorimmunität durch Injektion von Hybridzellen
WO1998008541A1 (en) * 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
AU721697B2 (en) * 1997-01-10 2000-07-13 Biogen Idec Ma Inc. Methods of therapeutic administration of anti-CD40L compounds
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
WO2000036103A1 (en) 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
AU2845400A (en) * 1998-12-24 2000-07-31 Phairson Medical Inc. Treatment and prevention of immune rejection reactions
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
WO2001000679A2 (en) * 1999-06-29 2001-01-04 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001066141A1 (fr) * 2000-03-06 2001-09-13 Eisai Co., Ltd. Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2405632A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
JP2003535592A (ja) * 2000-06-06 2003-12-02 アイデック ファーマスーティカルズ コーポレイション ヒトｇｐ３９に対する非アゴニスト抗体、含有する組成物、およびその治療的使用
PL212205B1 (pl) 2000-07-03 2012-08-31 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU2002220165A1 (en) * 2000-11-14 2002-05-27 The University Of Louisville Research Foundation, Inc. Non-lethal methods for conditioning a recipient for bone marrow transplantation
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2003220820A1 (en) * 2002-04-03 2003-10-27 Eisai Co., Ltd. Remedies for pemphigus containing cd40l antagonist as the active ingredient
DE60305919T2 (de) * 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
CN1326878C (zh) * 2003-04-29 2007-07-18 中国抗体制药有限公司 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
NZ544486A (en) * 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
DK3718564T3 (da) 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US8785140B2 (en) * 2005-02-02 2014-07-22 New South Innovations Pty Limited Cd4+ Cd25+ T-cells activated to a specific antigen
CN100423775C (zh) * 2005-04-15 2008-10-08 中国农业科学院兰州兽医研究所 牛衣原体病灭活疫苗及其制备与检验方法
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
CA2646329C (en) * 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
MX380352B (es) * 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
US8569059B2 (en) 2006-08-02 2013-10-29 Newsouth Innovations Pty Limited Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2052848A1 (de) 2007-10-27 2009-04-29 Joint Solar Silicon GmbH & Co. KG Aufbereitung von Formlingen aus Reinstsilizium
RS51975B (sr) * 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
US8911739B2 (en) 2009-02-10 2014-12-16 Trustees Of Columbia University In The City Of New York Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
DK3138854T3 (da) * 2009-03-10 2022-04-11 Baylor Res Institute Antistoffer mod CD40
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
TN2018000021A1 (en) 2015-07-14 2019-07-08 Immunext Inc ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
CA2946465C (en) 2015-11-12 2022-03-29 Delta Faucet Company Ozone generator for a faucet
EP4368637A3 (de) 2016-05-20 2024-07-10 Regeneron Pharmaceuticals, Inc. Verfahren zur durchbrechung einer immunologischen toleranz unter verwendung mehrerer guide-rnas
AU2018271915B2 (en) 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
KR102142499B1 (ko) * 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
CA2312667C (en) * 1991-10-25 2002-11-19 Immunex Corporation Novel cytokine
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
ATE188487T1 (de) * 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
CN1134113A (zh) 1996-10-23
FI105528B (fi) 2000-09-15
JP3007977B2 (ja) 2000-02-14
US5876718A (en) 1999-03-02
NO960862D0 (no) 1996-03-01
IL110855A (en) 1999-04-11
GR3033095T3 (en) 2000-08-31
US5747037A (en) 1998-05-05
NO960861L (no) 1996-04-30
WO1995006666A1 (en) 1995-03-09
US7722874B2 (en) 2010-05-25
CN1127351C (zh) 2003-11-12
DE69411025T2 (de) 1999-01-07
JP2991499B2 (ja) 1999-12-20
US6312692B1 (en) 2001-11-06
PT721469E (pt) 2000-04-28
JP3098739B2 (ja) 2000-10-16
DK0721346T3 (da) 1999-03-22
FI106306B (fi) 2001-01-15
WO1995006481A1 (en) 1995-03-09
AU7642994A (en) 1995-03-22
AU3518397A (en) 1997-10-30
US20060222649A1 (en) 2006-10-05
DE69422523T2 (de) 2000-10-12
NZ549136A (en) 2008-02-29
ATE167062T1 (de) 1998-06-15
NO960861D0 (no) 1996-03-01
FI960980A7 (fi) 1996-04-30
DE69411025D1 (de) 1998-07-16
IL110855A0 (en) 1994-11-28
US20020187135A1 (en) 2002-12-12
ES2120067T3 (es) 1998-10-16
HU9600522D0 (en) 1996-04-29
DE69422523D1 (de) 2000-02-10
FI960978A0 (fi) 1996-03-01
HUT74246A (en) 1996-11-28
JPH11189543A (ja) 1999-07-13
CN1149299A (zh) 1997-05-07
EP0721469B1 (de) 2000-01-05
GR3027658T3 (en) 1998-11-30
EP0721346A1 (de) 1996-07-17
HUT74250A (en) 1996-11-28
HU218610B (hu) 2000-10-28
FI960978L (fi) 1996-04-29
ES2143553T3 (es) 2000-05-16
NO321098B1 (no) 2006-03-20
NO960862L (no) 1996-04-30
FI960980A0 (fi) 1996-03-01
HU9600521D0 (en) 1996-04-29
EP0721346B1 (de) 1998-06-10
AU678532B2 (en) 1997-05-29
NZ273207A (en) 1997-09-22
HU220296B (hu) 2001-11-28
JPH09502186A (ja) 1997-03-04
AU7644594A (en) 1995-03-22
CN100341896C (zh) 2007-10-10
NO321036B1 (no) 2006-03-06
NZ273221A (en) 2001-09-28
JPH09502096A (ja) 1997-03-04
DK0721469T3 (da) 2000-05-01
AU707110B2 (en) 1999-07-01
EP0721469A1 (de) 1996-07-17
AU696235B2 (en) 1998-09-03

Similar Documents

Publication Publication Date Title
ATE188487T1 (de) Anti-gp39 antikoerper und deren verwendungen
Londei et al. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis.
Rosa et al. Bone marrow CD8 T cells are in a different activation state than those in lymphoid periphery
GR3036951T3 (en) Cells with multiple altered epitopes on a surface antigen for use in transplantation
WO1995034320A3 (en) Methods for inhibiting antigen specific t cell responses
AU3925295A (en) Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
TW272197B (de)
EP3177711B1 (de) Verwendung von liganden für zu festen trägern konjugierten rezeptor für programmierten zelltod zur expansion von humanen regulatorischen t-zellen
Viale et al. TCR gamma/delta positive lymphocytes after allogeneic bone marrow transplantation
Krummel et al. Thirty–six views of T–cell recognition
Luciani et al. Self-sparing of long-term in vitro-cloned or uncloned cytotoxic T lymphocytes.
Lanzavecchia Clonal sketches of the immune response.
ATE403867T1 (de) Evaluierung adjuvanshaltiger impfstoffe
RUSSELL Antilymphocyte serum as an immunosuppressive agent
Lomo et al. Flexibility of the Thyroiditogenic T Cell Repertoire for Murine Autoimmune Thyroiditis in CD8-Deficient (B2m-/-) and T Cell Receptor VBC Congenic Mice
Marx Thymic hormones: inducers of T cell maturation
Roehm et al. Helper signals in B lymphocyte differentiation
Smith et al. Stabilized analogs of thymopentin. 3. Evaluation of ketomethylene pseudopeptides for antiarthritic properties
Rust et al. Immobilized staphylococcal enterotoxin A is sufficient to induce T cell proliferation
Bass Two types of T helper cells in mice: Differences in cellular immune functions and cytokine secretion--selective reduction of one type after total lymphoid irradiation
Robert T Lymphocyte Recognition of Antigens
Qian et al. of March 2, 2014.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee